Literature DB >> 15650854

Efficacy of topical nerve growth factor treatment in dogs affected by dry eye.

Marco Coassin1, Alessandro Lambiase, Nicola Costa, Alessandra De Gregorio, Roberto Sgrulletta, Marta Sacchetti, Luigi Aloe, Stefano Bonini.   

Abstract

BACKGROUND: Preliminary data show that nerve growth factor (NGF) may improve tear production in humans. We evaluated the efficacy of topical NGF treatment in dogs who developed dry eye after the excision of the third eyelid lacrimal gland.
METHODS: English Bulldogs (2- to 6-year-old males and females) that had undergone the surgical removal of the prolapsed lacrimal gland of the third eyelid in both eyes at the age of 3-6 months developed chronic keratoconjunctivitis sicca associated with a decrease of Schirmer tear test I values after at least 1 year. One eye, randomly selected, of each dog was treated twice daily with 100 microl of NGF ointment for 1 month, while the fellow eye was used as control and treated with the ointment vehicle only. At baseline and after 1 month of NGF treatment the following examinations were performed: corneal evaluation by slit lamp, fluorescein staining, Schirmer tear test I, tear ferning test, corneal esthesiometry by cotton swab and conjunctival impression cytology.
RESULTS: Topical application of NGF caused a significant improvement of all the evaluated parameters compared with baseline values. In contrast, in the control eyes there was no significant difference between the values measured before and after treatment. In particular, after NGF treatment superficial punctate keratopathy was resolved, corneal haze was reduced from stage 4 to stage 2 and Schirmer test values increased (17.2+/-1.7 mm/min vs 4.5+/-1.3 mm/min; p<0.05), as did the tear mucous component (as demonstrated by ferning test: 2.0+/-0.0 vs 4.0+/-0.0; p<0.05); conjunctival impression cytology evaluation demonstrated the presence of numerous mucous filaments and a significant increase in conjunctival goblet cell density (102.7+/-68.3 vs. 18.2+/-14.3 cell x field; p<0.05). Topical NGF treatment improved corneal sensitivity in two of three eyes.
CONCLUSIONS: This open study suggests that topical application of NGF may enhance the production and functional characteristics in tear film, with an improvement of ocular surface signs in dogs with surgically induced dry eye. These results suggest the possibility of performing further, larger, controlled studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650854     DOI: 10.1007/s00417-004-0955-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  34 in total

Review 1.  The ocular surface and tear film and their dysfunction in dry eye disease.

Authors:  M Rolando; M Zierhut
Journal:  Surv Ophthalmol       Date:  2001-03       Impact factor: 6.048

2.  Mitogenic and antiapoptotic effects of various growth factors on human corneal fibroblasts.

Authors:  Ryoji Yanai; Naoyuki Yamada; Naruji Kugimiya; Makoto Inui; Teruo Nishida
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

3.  Conjunctival impression cytology from dogs with keratoconjunctivitis sicca. Pre- and post-treatment with topical cyclosporine.

Authors:  D I Bounous; K L Krenzer; R L Kaswan; S G Hirsh
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

4.  Topical treatment with nerve growth factor for corneal neurotrophic ulcers.

Authors:  A Lambiase; P Rama; S Bonini; G Caprioglio; L Aloe
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

Review 5.  Keratocyte apoptosis: implications on corneal wound healing, tissue organization, and disease.

Authors:  S E Wilson; W J Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-02       Impact factor: 4.799

Review 6.  The nerve growth factor 35 years later.

Authors:  R Levi-Montalcini
Journal:  Science       Date:  1987-09-04       Impact factor: 47.728

7.  Immunolocalization of muscarinic and VIP receptor subtypes and their role in stimulating goblet cell secretion.

Authors:  J D Ríos; D Zoukhri; I M Rawe; R R Hodges; J D Zieske; D A Dartt
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-05       Impact factor: 4.799

8.  Topical treatment with nerve growth factor for neurotrophic keratitis.

Authors:  S Bonini; A Lambiase; P Rama; G Caprioglio; L Aloe
Journal:  Ophthalmology       Date:  2000-07       Impact factor: 12.079

9.  Growth factors modulate clonal growth and differentiation of cultured rabbit limbal and corneal epithelium.

Authors:  F E Kruse; S C Tseng
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-05       Impact factor: 4.799

10.  Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study.

Authors:  Michael Küchle; Claus Cursiefen; Nhung X Nguyen; Achim Langenbucher; Berthold Seitz; Hartmut Wenkel; Peter Martus; Gottfried O H Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-06-21       Impact factor: 3.117

View more
  17 in total

1.  The TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on neurobiology.

Authors:  Fiona Stapleton; Carl Marfurt; Blanka Golebiowski; Mark Rosenblatt; David Bereiter; Carolyn Begley; Darlene Dartt; Juana Gallar; Carlos Belmonte; Pedram Hamrah; Mark Willcox
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-18       Impact factor: 4.799

Review 2.  [Current therapeutic options in Sjögren's syndrome].

Authors:  A Hansen; T Dörner
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

3.  Diagnostic Ophthalmology.

Authors:  Marina L Leis; Lynne S Sandmeyer
Journal:  Can Vet J       Date:  2018-09       Impact factor: 1.008

Review 4.  [Novel current and future therapy options for treatment of dry eye disease].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2018-02       Impact factor: 1.059

5.  Dry eye disease: A review of diagnostic approaches and treatments.

Authors:  Hui Lin; Samuel C Yiu
Journal:  Saudi J Ophthalmol       Date:  2014-06-24

6.  Topical treatment with nerve growth factor in an animal model of herpetic keratitis.

Authors:  Alessandro Lambiase; Marco Coassin; Nicola Costa; Paolo Lauretti; Alessandra Micera; Emiliano Ghinelli; Luigi Aloe; Paolo Rama; Stefano Bonini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-05-04       Impact factor: 3.117

7.  Nerve growth factor promotes corneal epithelial migration by enhancing expression of matrix metalloprotease-9.

Authors:  Tomas Blanco-Mezquita; Carmen Martinez-Garcia; Rui Proença; James D Zieske; Stefano Bonini; Alessandro Lambiase; Jesus Merayo-Lloves
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-04       Impact factor: 4.799

8.  Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.

Authors:  Karen Meerovitch; Gail Torkildsen; John Lonsdale; Heidi Goldfarb; Teresa Lama; Garth Cumberlidge; George W Ousler
Journal:  Clin Ophthalmol       Date:  2013-06-26

9.  The effect of nerve growth factor on differentiation of corneal limbal epithelial cells to conjunctival goblet cells in vitro.

Authors:  Weiwei Li; Xuguang Sun; Zhiqun Wang; Ran Li; Li Li
Journal:  Mol Vis       Date:  2010-12-15       Impact factor: 2.367

10.  Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro.

Authors:  Chloé Clouzeau; David Godefroy; Luisa Riancho; William Rostène; Christophe Baudouin; Françoise Brignole-Baudouin
Journal:  Mol Vis       Date:  2012-04-06       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.